Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
About this trial
This is an interventional treatment trial for Stable Coronary Artery Disease focused on measuring Berberine, Gut microbiota, Endothelial function
Eligibility Criteria
Inclusion Criteria:
Patients with stable coronary artery disease undergo elective PCI >8 weeks, but ≤40 weeks
Exclusion Criteria:
- Planned coronary revascularization, including PCI and coronary artery bypass graft (CABG) during the study period.
- Subjects with uncontrolled high blood pressure
- Recent (within 4 weeks) dose adjustment of any standard therapy agents
- Recent (within 4 weeks) use of berberine
- History of intolerance to berberine.
- Cr>1.5mg/dL; ALT level exceeds the upper limit of 3 times
- Heart failure or LVEF <50%
- Uncontrolled arrhythmia
- Pregnancy or lactation
- Malignant tumor or life expectancy is less than half a year
- Subjects who can not complete the follow-up
Sites / Locations
- Peking Union Medical College Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Berberine+standard therapy Arm
Standard therapy Arm
In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.